Filings & corporate actions
80 results filed
CSVNext results · Q2 FY27
Expected 22 Oct 2026 – 31 Oct 2026
Estimate: filed 22–31 days after quarter end, last 5 times
Dividend
₹5.00 per share · last 24 Jul 2026
2026
- 10 AugresultsResults · Q1 FY27 · consolidated and standalone+0.2%NSE
- 24 JuldividendDividend · ₹5.00 per share-0.6%
- 21 JulshareholdingShareholding · 30 Jun 2026-1.6%NSE
- 22 MayresultsResults · Q4 FY26 · consolidated and standalone+0.1%NSE
- 18 AprshareholdingShareholding · 31 Mar 2026-0.6%NSE
- 6 FebresultsResults · Q3 FY26 · consolidated and standalone-3.7%NSE
- 21 JanshareholdingShareholding · 31 Dec 2025-0.4%NSE
Reaction to results · all yearsrose on day 0 in 34 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 10 Aug 2026 | +0.2% | -10.0% | +3.6% | 5.5× |
| Q4 FY26 | 22 May 2026 | +0.1% | -3.1% | -3.4% | 2.7× |
| Q3 FY26 | 6 Feb 2026 | -3.7% | -6.2% | -15.7% | 3.2× |
| Q2 FY26 | 31 Oct 2025 | +6.2% | +1.5% | -0.2% | 5.2× |
| Q1 FY26 | 29 Jul 2025 | +7.2% | -4.2% | -11.3% | 6.7× |
| Q4 FY25 | 16 May 2025 | +1.5% | +18.6% | +19.1% | 3.4× |
| Q3 FY25 | 31 Jan 2025 | +0.4% | +2.7% | -7.7% | 0.4× |
| Q2 FY25 | 25 Oct 2024 | +3.6% | +18.3% | +7.4% | 1.0× |
| Q1 FY25 | 19 Jul 2024 | -3.4% | -3.5% | +19.6% | 1.8× |
| Q4 FY24 | 30 May 2024 | +0.8% | +2.0% | +4.8% | 0.6× |
| Q3 FY24 | 2 Feb 2024 | -1.8% | -1.0% | -3.5% | 1.4× |
| Q2 FY24 | 28 Oct 2023 | -4.1% | +0.7% | +8.9% | 3.0× |
| Q1 FY24 | 20 Jul 2023 | -1.7% | -5.3% | +12.7% | 0.8× |
| Q4 FY23 | 30 May 2023 | -0.7% | +6.2% | +21.5% | 0.8× |
| Q3 FY23 | 3 Feb 2023 | -3.5% | -6.8% | -11.4% | 1.4× |
| Q2 FY23 | 22 Oct 2022 | -1.1% | +13.4% | +11.4% | 0.2× |
| Q1 FY23 | 2 Aug 2022 | -3.6% | -2.1% | -9.1% | 2.6× |
| Q4 FY22 | 27 May 2022 | +0.6% | -1.4% | -13.1% | 1.3× |
| Q3 FY22 | 4 Feb 2022 | -7.1% | -13.1% | -24.6% | 6.7× |
| Q2 FY22 | 22 Oct 2021 | +0.3% | +1.0% | -1.1% | 1.5× |
| Q1 FY22 | 23 Jul 2021 | -0.4% | -1.2% | -14.7% | 1.7× |
| Q4 FY21 | 6 Jun 2021 | -6.0% | -8.8% | -12.7% | 3.1× |
| Q3 FY21 | 5 Feb 2021 | +5.0% | -6.7% | -17.9% | 0.1× |
| Q2 FY21 | 5 Nov 2020 | -0.6% | -1.3% | +18.7% | 1.7× |
| Q1 FY21 | 4 Sept 2020 | -6.1% | -8.1% | -11.0% | 1.4× |
| Q4 FY20 | 30 May 2020 | +5.0% | +28.8% | +46.9% | 0.5× |
| Q3 FY20 | 31 Jan 2020 | -6.0% | -6.6% | -14.2% | 0.4× |
| Q2 FY20 | 25 Oct 2019 | -6.8% | -4.0% | -8.6% | 1.9× |
| Q1 FY20 | 26 Jul 2019 | -1.5% | -6.2% | -6.6% | 0.9× |
| Q4 FY19 | 17 May 2019 | -5.1% | -9.8% | -19.1% | 3.9× |
| Q3 FY19 | 6 Feb 2019 | +1.7% | +0.8% | +6.4% | 1.0× |
| Q2 FY19 | 24 Oct 2018 | +0.5% | +3.1% | +4.8% | 0.4× |
| Q1 FY19 | 7 Aug 2018 | -2.2% | -4.4% | +7.7% | 1.8× |
| Q4 FY18 | 8 Jun 2018 | +1.7% | +1.9% | -6.1% | 1.4× |
| Q3 FY18 | 22 Jan 2018 | +0.5% | +2.9% | +11.8% | 0.5× |
| Q2 FY18 | 31 Oct 2017 | +0.2% | +1.4% | +1.0% | 0.5× |
| Q1 FY18 | 3 Aug 2017 | -2.4% | -4.8% | -1.5% | 0.6× |
| Q4 FY17 | 12 Jun 2017 | -1.8% | -7.6% | -2.8% | 0.5× |
| Q3 FY17 | 10 Feb 2017 | -1.6% | +1.0% | +12.6% | 0.5× |
| Q2 FY17 | 8 Nov 2016 | +0.2% | -4.1% | +5.5% | 1.1× |
| Q1 FY17 | 22 Sept 2016 | -1.2% | -6.0% | +9.4% | 0.5× |
| Q4 FY16 | 25 May 2016 | -4.3% | +2.5% | -5.6% | 2.9× |
| Q3 FY16 | 9 Feb 2016 | -4.2% | -12.2% | +0.6% | 0.8× |
| Q2 FY16 | 2 Nov 2015 | +4.4% | -1.1% | +9.5% | 1.2× |
| Q1 FY16 | 11 Aug 2015 | -0.6% | +12.6% | +1.7% | 4.3× |
| Q4 FY15 | 19 May 2015 | -1.2% | +0.1% | -1.6% | 0.2× |
| Q3 FY15 | 3 Feb 2015 | -9.2% | -8.8% | -8.9% | 1.0× |
| Q2 FY15 | 29 Oct 2014 | -11.3% | -17.4% | -18.7% | 9.8× |
| Q1 FY15 | 11 Aug 2014 | -1.5% | +1.1% | +0.9% | 0.8× |
| Q4 FY14 | 27 May 2014 | +0.9% | -1.9% | +12.0% | 3.4× |
| Q3 FY14 | 7 Feb 2014 | -2.2% | -18.3% | -2.5% | 1.2× |
| Q2 FY14 | 6 Nov 2013 | +4.5% | +1.5% | +26.1% | 1.3× |
| Q1 FY14 | 5 Aug 2013 | +2.1% | -1.1% | -23.6% | 0.8× |
| Q4 FY13 | 23 May 2013 | +1.5% | +8.3% | -1.3% | 0.3× |
| Q3 FY13 | 4 Feb 2013 | -1.0% | -2.9% | -18.5% | 1.9× |
| Q2 FY13 | 7 Nov 2012 | -1.6% | -1.3% | +9.1% | 0.8× |
| Q1 FY13 | 23 Jul 2012 | -1.8% | -6.8% | -6.0% | 14.9× |
| Q4 FY12 | 10 May 2012 | -2.3% | +4.0% | -2.3% | 1.6× |
| Q3 FY12 | 6 Feb 2012 | +1.4% | +15.0% | +3.1% | 1.6× |
| Q2 FY12 | 1 Nov 2011 | +2.3% | +7.0% | -8.8% | 3.1× |
| Q1 FY12 | 9 Aug 2011 | -2.3% | -3.2% | +13.6% | 1.1× |
| Q4 FY11 | 10 May 2011 | +5.0% | +5.0% | +4.1% | 7.5× |
| Q3 FY11 | 14 Feb 2011 | -0.9% | -18.6% | -21.5% | 2.8× |
| Q2 FY11 | 11 Nov 2010 | -1.6% | -3.4% | -13.3% | 0.9× |
| Q1 FY11 | 27 Jul 2010 | -2.1% | +1.2% | -3.5% | 2.0× |
| Q4 FY10 | 10 May 2010 | +2.4% | +0.2% | +2.6% | 1.0× |
| Q3 FY10 | 21 Jan 2010 | +1.3% | -2.9% | -4.5% | 2.0× |
| Q2 FY10 | 22 Oct 2009 | -4.6% | +2.8% | +37.5% | 3.2× |
| Q1 FY10 | 14 Jul 2009 | +7.2% | +8.0% | +30.1% | 9.7× |
| Q4 FY09 | 28 Apr 2009 | -7.9% | +16.7% | +48.9% | 0.5× |
| Q3 FY09 | 27 Jan 2009 | +0.6% | -7.5% | -10.7% | 0.3× |
| Q2 FY09 | 14 Oct 2008 | -7.5% | -18.7% | -13.1% | 0.8× |
| Q1 FY09 | 15 Jul 2008 | +2.5% | +18.6% | +20.6% | 5.1× |
| Q4 FY08 | 22 Apr 2008 | +2.4% | +4.4% | -1.8% | 1.9× |
| Q3 FY08 | 30 Jan 2008 | -1.7% | +11.6% | +13.8% | 0.3× |
| Q2 FY08 | 16 Oct 2007 | +5.5% | +2.9% | +4.0% | 2.2× |
| Q1 FY08 | 17 Jul 2007 | +0.4% | -2.6% | -2.2% | 3.7× |
| Q4 FY07 | 27 Apr 2007 | -0.2% | -0.6% | +5.2% | 0.4× |
| Average | -0.8% | -0.5% | +1.2% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+17.3%
Profit YoY-45.0%
Interest cost YoY-0.6%
Revenue QoQ-2.6%
Profit QoQ-52.7%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +27.9% | +10.3% | — | +3.2% | -0.5% | — |
| Profit | -23.7% | — | — | -17.3% | -12.8% | — |
Key data
CSVOpen982.00
Day range970.10 – 996.60
52-week range786.05 – 1,184.80
From 52w high-16.5%
RSI (14)47.1
ATR (14)36.67
Volume1.75L
Avg volume (20D)3.26L
Rel volume0.54×
Volatility (1Y)29.6%
Turnover₹17.3Cr
SMA 50 / 200957.90 / 956.07
Delivery percentage
Latest · 6 Oct 202658.5%
20-day avg47.6%
1-year avg51.7%
Percentile (own history)84th
Range5.2–100.0%
Sessions1,731
Over the last 20 sessions JUBLPHARMA settled 47.6% of its traded quantity, which is above average for an NSE equity. Its one-year average is 51.7%, so recent sessions are running 4.1 points lower than usual. The latest session ranks higher than 84% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.77% | -6.72% | +8.95% | +1.06% | +17.86% | -5.15% |
Valuation
CSVMarket cap₹15,756 Cr
P/E (TTM)44.8
EPS (TTM)22.06
Shares outstanding15.80Cr
Listed16 Jun 2003
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 1,966.4 | 2,122.5 | 2,290.0 | 2,229.4 |
| YoY chg | +12.2% | +16.5% | +18.7% | +17.3% |
| Net profit (₹ Cr) | 119.9 | 55.8 | 119.3 | 56.4 |
| YoY chg | +17.0% | -44.6% | -21.2% | -45.0% |
| Net margin | 6.1% | 2.6% | 5.2% | 2.5% |
| EPS | 7.57 | 3.52 | 7.52 | 3.56 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 47.68% · public 51.77%2021-092026-06
- Promoter
- Public and others
- Promoter
- 47.68%
- Public
- 51.77%
- Promoter change
- 0.00 pp
- Filed
- 21 Jul 2026
- FII
- 15.87%
- DII
- 12.40%
- Promoter pledged
- 6.58%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,680.3 | 1,677.1 | 175.9 | 1,731.7 | 1,752.3 | 1,821.7 | 1,928.8 | 1,900.7 | 1,966.4 | 2,122.5 | 2,290.0 | 2,229.4 | |
| Other income | 9.9 | 35.8 | 1.4 | 14.0 | 21.7 | 9.2 | 11.9 | 12.0 | 9.8 | 20.5 | 23.7 | 19.9 | |
| Total income | 1,690.2 | 1,712.9 | 177.3 | 1,745.7 | 1,774.0 | 1,830.9 | 1,940.7 | 1,912.7 | 1,976.2 | 2,143.0 | 2,313.7 | 2,249.3 | |
| Total expenses | 1,601.2 | 1,625.0 | 166.1 | 1,641.9 | 1,615.3 | 1,681.2 | 1,731.3 | 1,758.2 | 1,780.0 | 2,009.8 | 2,124.0 | 2,162.9 | |
| └ Finance costs | 66.1 | 71.3 | 7.3 | 71.0 | 61.0 | 55.6 | 52.7 | 49.0 | 50.2 | 56.1 | 56.5 | 54.2 | |
| └ Depreciation | 96.6 | 94.6 | 10.1 | 90.7 | 91.4 | 91.3 | 95.2 | 98.1 | 104.8 | 120.7 | 116.8 | 127.3 | |
| Profit before tax | 89.0 | 87.9 | (5.7) | 499.7 | 144.5 | 130.8 | 206.1 | 154.5 | 190.4 | 93.5 | 176.0 | 86.4 | |
| Tax expense | 35.9 | 34.6 | 0.8 | 17.9 | 41.9 | 29.8 | 54.7 | 51.9 | 70.4 | 37.6 | 56.7 | 30.0 | |
| Net profit | 62.1 | 66.4 | (6.2) | 481.8 | 102.5 | 100.7 | 151.3 | 102.5 | 119.9 | 55.8 | 119.3 | 56.4 | |
| EPS | 3.94 | 4.22 | -3.69 | 30.44 | 6.47 | 6.37 | 9.71 | 6.49 | 7.59 | 3.52 | 7.55 | 3.57 | |
| Net margin | 3.70% | 3.96% | -3.51% | 27.82% | 5.85% | 5.53% | 7.84% | 5.39% | 6.10% | 2.63% | 5.21% | 2.53% | |
| PBT margin | 5.30% | 5.24% | -3.25% | 28.86% | 8.25% | 7.18% | 10.69% | 8.13% | 9.68% | 4.41% | 7.69% | 3.88% | |
| Tax rate | 40.34% | 39.36% | — | 3.58% | 29.00% | 22.78% | 26.54% | 33.59% | 36.97% | 40.21% | 32.22% | 34.72% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 10 Aug 2026.
JUBLPHARMA at a glance
- JUBLPHARMA closed at ₹989.2 on 6 Oct 2026, +0.77% on the day, -5.1% over one year, 16.5% below its 52-week high of ₹1,184.8.
- Delivery was 58.5% of traded quantity on 6 Oct 2026, the 84th percentile of its own 1,731 sessions with a reading (20-session average 47.6%, 1-year average 51.7%).
- Market capitalisation is ₹15,756 crore at a trailing P/E of 44.8 (trailing EPS ₹22.06).
- Q1 FY27 results (consolidated, filed 10 Aug 2026): revenue ₹2,229 crore (+17.3% year on year), net profit ₹56 crore (-45.0%); the price moved +0.2% on the first session after.
- Promoters held 47.68% at 30 Jun 2026, unchanged on the previous filing, with 6.58% of promoter shares pledged.
- Q2 FY27 results are expected between 22 Oct 2026 and 31 Oct 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE700A01033
SeriesEQ
Listed16 Jun 2003
History from30 Sept 2003
Sessions5,713
Turnover rank#595
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE